PT3258951T - Anticorpos anti-pvrig e métodos de utilização - Google Patents

Anticorpos anti-pvrig e métodos de utilização

Info

Publication number
PT3258951T
PT3258951T PT167076033T PT16707603T PT3258951T PT 3258951 T PT3258951 T PT 3258951T PT 167076033 T PT167076033 T PT 167076033T PT 16707603 T PT16707603 T PT 16707603T PT 3258951 T PT3258951 T PT 3258951T
Authority
PT
Portugal
Prior art keywords
methods
pvrig antibodies
pvrig
antibodies
Prior art date
Application number
PT167076033T
Other languages
English (en)
Original Assignee
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55453315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3258951(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Compugen Ltd filed Critical Compugen Ltd
Publication of PT3258951T publication Critical patent/PT3258951T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/106—Picornaviridae (F), e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
PT167076033T 2015-02-19 2016-02-19 Anticorpos anti-pvrig e métodos de utilização PT3258951T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118208P 2015-02-19 2015-02-19
US201562141120P 2015-03-31 2015-03-31
US201562235823P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
PT3258951T true PT3258951T (pt) 2020-08-18

Family

ID=55453315

Family Applications (3)

Application Number Title Priority Date Filing Date
PT167076033T PT3258951T (pt) 2015-02-19 2016-02-19 Anticorpos anti-pvrig e métodos de utilização
PT171923253T PT3295951T (pt) 2015-02-19 2016-02-19 Anticorpos anti-pvrig e métodos de utilização
PT192142313T PT3653221T (pt) 2015-02-19 2016-02-19 Anticorpos anti-pvrig e métodos de utilização

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT171923253T PT3295951T (pt) 2015-02-19 2016-02-19 Anticorpos anti-pvrig e métodos de utilização
PT192142313T PT3653221T (pt) 2015-02-19 2016-02-19 Anticorpos anti-pvrig e métodos de utilização

Country Status (21)

Country Link
US (8) US10227408B2 (pt)
EP (4) EP3653221B1 (pt)
JP (2) JP7115856B2 (pt)
KR (2) KR102669294B1 (pt)
CN (2) CN107580500B (pt)
AU (3) AU2016219835B2 (pt)
CY (2) CY1122970T1 (pt)
DK (3) DK3653221T5 (pt)
ES (3) ES2786651T3 (pt)
HR (3) HRP20221284T1 (pt)
HU (3) HUE061084T2 (pt)
IL (3) IL326240A (pt)
LT (3) LT3295951T (pt)
MX (2) MX374853B (pt)
PL (3) PL3258951T3 (pt)
PT (3) PT3258951T (pt)
RU (1) RU2732042C2 (pt)
SG (1) SG11201706583PA (pt)
SI (2) SI3295951T1 (pt)
WO (1) WO2016134333A1 (pt)
ZA (1) ZA201706323B (pt)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3243494B2 (ja) 1999-05-18 2002-01-07 独立行政法人産業技術総合研究所 チオフェン水素化脱硫用触媒及びその製造方法
WO2011105424A1 (ja) * 2010-02-23 2011-09-01 国立大学法人東京大学 樹状細胞免疫受容体刺激剤
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
DK3653221T5 (da) 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
EP3288570A4 (en) 2015-04-29 2018-11-21 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2016196389A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
KR20180054639A (ko) * 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
US10407484B2 (en) * 2015-09-02 2019-09-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
CN109996868A (zh) 2016-09-23 2019-07-09 弗雷德哈钦森癌症研究中心 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
JP7037577B2 (ja) 2017-03-15 2022-03-16 フレッド ハッチンソン キャンサー リサーチ センター 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
CA3063563A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
JP7348072B2 (ja) 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
EP3655026A4 (en) 2017-07-17 2021-07-28 Janssen Biotech, Inc. ANTIGBINDING REGIONS AGAINST FIBRONECTIN TYPE III DOMAINS AND METHOD OF USING THEREOF
US12398191B2 (en) 2017-08-11 2025-08-26 Fred Hutchinson Cancer Center BRAF-specific TCRs and uses thereof
US12350312B2 (en) 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
CN111051349A (zh) 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
EP3678689A1 (en) 2017-09-06 2020-07-15 Fred Hutchinson Cancer Research Center Strep-tag specific binding proteins and uses thereof
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
US10752691B2 (en) 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
KR102892725B1 (ko) 2018-05-09 2025-12-01 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 넥틴4에 특이적인 항체
EP3802604A1 (en) 2018-05-31 2021-04-14 Glyconex Inc. Therapeutic antibodies binding to biantennary lewis b and lewis y antigens
KR20210016448A (ko) * 2018-06-01 2021-02-15 컴퓨젠 엘티디. 항-pvrig/항-tigit 이중특이적 항체 및 사용 방법
CN119841953A (zh) 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
MX2021000745A (es) 2018-07-20 2021-03-26 Surface Oncology Inc Composiciones anti-cd112r y metodos.
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
CN112912387A (zh) 2018-08-22 2021-06-04 弗雷德哈钦森癌症研究中心 靶向kras或her2抗原的免疫疗法
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
JP2022500037A (ja) * 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗ｉｌ４受容体抗体
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US20240165232A1 (en) 2018-09-24 2024-05-23 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CA3119188A1 (en) 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center T cell receptors specific for mesothelin and their use in immunotherapy
FI3898668T3 (fi) 2018-12-19 2023-11-28 Humabs Biomed Sa B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
KR20210126638A (ko) * 2019-02-06 2021-10-20 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 항-trem1 항체 및 관련 방법
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
CN114026116A (zh) 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
EP4003417A2 (en) * 2019-07-29 2022-06-01 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP7737978B2 (ja) 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Ｗｔ－１に特異的なｔ細胞免疫療法
CA3152511A1 (en) 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
JP2023500651A (ja) * 2019-11-04 2023-01-10 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体製剤および抗ｐｄ－１抗体による併用療法
CN114746116A (zh) * 2019-11-15 2022-07-12 表面免疫肿瘤学公司 用于免疫疗法的组合物和方法
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
CA3170025A1 (en) * 2020-03-13 2021-09-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pvrig binding protein and its medical uses
PH12022553569A1 (en) 2020-06-24 2023-04-12 Humabs Biomed Sa Engineered hepatitis b virus neutralizing antibodies and uses thereof
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
TW202216778A (zh) * 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN116724053A (zh) 2020-09-24 2023-09-08 弗雷德哈钦森癌症中心 靶向sox2抗原的免疫治疗
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
EP4219738A4 (en) * 2020-09-25 2024-10-02 Suzhou Ersheng Biopharmaceutical Co., Ltd DETECTION METHODS FOR TUMOR-SPECIFIC T CELLS
WO2022076353A1 (en) 2020-10-06 2022-04-14 Fred Hutchinson Cancer Research Center Compositions and methods for treating mage-a1-expressing disease
EP4232822A2 (en) * 2020-10-26 2023-08-30 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN112433055A (zh) * 2020-11-04 2021-03-02 上海药明生物技术有限公司 一种基于报告基因方法检测pvrig抗体的生物学活性的方法
WO2022132836A2 (en) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
WO2022165266A1 (en) 2021-01-28 2022-08-04 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
WO2022165275A2 (en) 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
WO2022171080A1 (zh) * 2021-02-09 2022-08-18 上海君实生物医药科技股份有限公司 抗cd112r抗体及其用途
MX2023009434A (es) * 2021-02-11 2023-08-15 Nectin Therapeutics Ltd Anticuerpos contra cd112r y usos de los mismos.
CN115925917A (zh) * 2021-03-08 2023-04-07 合肥天港免疫药物有限公司 抗pvrig蛋白抗体或抗体片段及其用途
JP2024511831A (ja) 2021-03-31 2024-03-15 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 抗原結合タンパク質およびそれらの組み合わせ
WO2022258049A1 (en) * 2021-06-10 2022-12-15 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric pvrig
EP4363450A1 (en) 2021-07-01 2024-05-08 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202317602A (zh) 2021-07-15 2023-05-01 福瑞德哈金森腫瘤中心 嵌合多肽
US20240343803A1 (en) 2021-07-30 2024-10-17 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
EP4403574A4 (en) 2021-09-15 2025-10-29 Jiangsu Hengrui Pharmaceuticals Co Ltd PD-1-Specific Protein and Its Pharmaceutical Use
WO2023040940A1 (zh) * 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
EP4403573A4 (en) 2021-09-15 2024-12-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING BISPECIFIC ANTI-PVRIG/TIGIT ANTIBODY
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CN115819582A (zh) * 2021-12-24 2023-03-21 合肥天港免疫药物有限公司 Pvrig的抗体或其抗原结合片段及其应用
CN114644711B (zh) * 2022-03-07 2025-03-04 南京诺艾新生物技术有限公司 重组抗人pvrig抗体及应用
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
US20240103010A1 (en) * 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN116925222A (zh) 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pvrig抗体、其药物组合物及用途
CN116925233A (zh) 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
TW202411246A (zh) 2022-05-23 2024-03-16 美商維爾生物科技股份有限公司 經工程化之b型肝炎病毒中和抗體及其用途
AU2023290487A1 (en) * 2022-06-14 2025-01-30 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
US20260035460A1 (en) 2022-07-28 2026-02-05 Adeboye Henry ADEWOYE, MD Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
CN120112553A (zh) * 2022-08-10 2025-06-06 广州百济神州生物制药有限公司 抗pvrig抗体和使用方法
CN117957254A (zh) * 2022-08-31 2024-04-30 石药集团巨石生物制药有限公司 抗pvrig抗体及其应用
WO2024098980A1 (en) * 2022-11-10 2024-05-16 Huahui Health Ltd. Anti-cd112r antibodies and use thereof
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
CN120476148A (zh) 2022-12-30 2025-08-12 杭州中美华东制药有限公司 一种靶向cd112r的抗体或其抗原结合片段及其应用
WO2024182443A2 (en) 2023-02-27 2024-09-06 Compugen Ltd. Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
KR20250156744A (ko) 2023-03-15 2025-11-03 상하이 맙젠 바이오텍 리미티드 Pd-1/pvrig/tigit 결합 단백질을 함유하는 약학적 조성물 및 이의 의약적 용도
TW202502812A (zh) * 2023-06-06 2025-01-16 大陸商上海藥明生物技術有限公司 抗pvrig抗體及其用途
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
CN120005023B (zh) * 2023-12-22 2025-12-26 华润生物医药有限公司 抗pvrig抗体及其用途
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
CN119193693B (zh) * 2024-08-06 2025-06-13 湖南农业大学 重组质粒及其制备方法、蛋白组合物、用途、疫苗、组合疫苗
CN120058919B (zh) * 2025-04-29 2025-07-18 浙江大学杭州国际科创中心 抗裂谷热病毒Gn蛋白的单抗及在病毒检测中的应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1165766A2 (en) 1999-03-05 2002-01-02 Incyte Pharmaceuticals, Inc. Human secretory proteins
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
WO2002090520A2 (en) 2001-05-09 2002-11-14 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
JP5401001B2 (ja) 2002-09-11 2014-01-29 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004058805A2 (en) * 2002-12-26 2004-07-15 Asahi Kasei Pharma Corporation T cell activating gene
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7622265B2 (en) 2005-02-22 2009-11-24 Genentech, Inc. Methods and compositions for modulating prostasin
EP1891107B1 (en) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
WO2007124283A2 (en) 2006-04-13 2007-11-01 Zymogenetics, Inc. Tetramerizing polypeptides and methods of use
WO2007121364A2 (en) 2006-04-13 2007-10-25 Zymogenetics, Inc. Tetramerizing polypeptides and methods of use
US20090318376A1 (en) 2006-06-15 2009-12-24 Korea Research Institute Of Bioscience And Biotechnology High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
JPWO2008044754A1 (ja) 2006-10-06 2010-02-18 武田薬品工業株式会社 癌の予防・治療剤
CA2694990A1 (en) * 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
WO2010109924A1 (ja) 2009-03-25 2010-09-30 国立大学法人東北大学 Ｌｈ型二重特異性抗体
TW201132813A (en) 2010-03-03 2011-10-01 Koo Foundation Sun Yat Sen Cancer Ct Methods for classifying and treating breast cancers
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
JP6033229B2 (ja) 2010-11-24 2016-11-30 レクシコン ファーマシューティカルズ インコーポレイテッド Ｎｏｔｕｍペクチンアセチルエステラーゼと結合する抗体
WO2012129488A2 (en) 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
WO2012156515A1 (en) 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
EP2723924A4 (en) 2011-06-22 2015-03-25 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
HK1200322A1 (en) 2011-10-24 2015-08-07 Abbvie Inc. Immunobinders directed against sclerostin
EP3202419A1 (en) 2012-06-06 2017-08-09 OncoMed Pharmaceuticals, Inc. Pvrig binding agents that modulate the hippo pathway and uses thereof
CN103073644B (zh) 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
BR112016000853A2 (pt) 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
KR102345173B1 (ko) 2014-03-14 2021-12-29 이나뜨 파르마 에스.에이. 증가된 안정성을 가진 인간화 항체
EP3169363A4 (en) 2014-07-16 2018-02-21 F. Hoffmann-La Roche AG Methods of treating cancer using tigit inhibitors and anti-cancer agents
MD4733C1 (ro) 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US20160152720A1 (en) 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
EP3221358B1 (en) 2014-11-18 2021-07-21 Janssen Pharmaceutica, N.V. Cd47 antibodies, methods, and uses
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
DK3653221T5 (da) 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
US10550173B2 (en) 2015-02-19 2020-02-04 Compugen, Ltd. PVRIG polypeptides and methods of treatment
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US10407484B2 (en) 2015-09-02 2019-09-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
PE20181046A1 (es) 2015-09-25 2018-07-03 Genentech Inc Anticuerpos anti-tigit y metodos de uso
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
WO2018017864A2 (en) 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
CR20190291A (es) 2016-12-23 2019-11-05 Serum Institute Of India Pvt Ltd Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
WO2018210898A1 (en) 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Reduction of application-related side reaction of a therapeutic antibody
JP7348072B2 (ja) 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
MA51747A (fr) 2018-02-08 2020-12-16 Amgen Inc Formulation d'anticorps pharmaceutique à ph faible
JP2023500651A (ja) 2019-11-04 2023-01-10 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体製剤および抗ｐｄ－１抗体による併用療法
US12462008B2 (en) 2021-04-23 2025-11-04 Beijing Boe Technology Development Co., Ltd. Unlocking control method and device, electronic apparatus, and computer-readable storage medium

Also Published As

Publication number Publication date
EP4129320A1 (en) 2023-02-08
CN107580500A (zh) 2018-01-12
ES2786651T3 (es) 2020-10-13
RU2017132214A (ru) 2019-03-19
IL326240A (en) 2026-03-01
DK3295951T3 (da) 2020-07-20
KR20240090732A (ko) 2024-06-21
ES2929293T3 (es) 2022-11-28
IL254039B2 (en) 2023-12-01
ZA201706323B (en) 2020-05-27
US20250333503A1 (en) 2025-10-30
JP7115856B2 (ja) 2022-08-09
IL254039B1 (en) 2023-08-01
HK1247568A1 (en) 2018-09-28
JP2022106783A (ja) 2022-07-20
IL304117A (en) 2023-09-01
SI3295951T1 (sl) 2020-10-30
US20170081408A1 (en) 2017-03-23
EP3295951B1 (en) 2020-04-22
DK3258951T3 (da) 2020-04-06
HRP20221284T1 (hr) 2022-12-23
US20210188974A1 (en) 2021-06-24
WO2016134333A1 (en) 2016-08-25
CN115350275A (zh) 2022-11-18
JP2018512443A (ja) 2018-05-17
PT3295951T (pt) 2020-07-21
EP3295951A1 (en) 2018-03-21
AU2020264349A1 (en) 2020-12-03
US11220542B2 (en) 2022-01-11
EP3258951A1 (en) 2017-12-27
HRP20200572T1 (hr) 2020-08-21
EP3653221A1 (en) 2020-05-20
KR102669294B1 (ko) 2024-05-23
AU2020264349B2 (en) 2024-05-02
RU2732042C2 (ru) 2020-09-10
US10227408B2 (en) 2019-03-12
US20180244774A1 (en) 2018-08-30
LT3653221T (lt) 2022-11-10
US20170029504A1 (en) 2017-02-02
CY1122970T1 (el) 2021-10-29
AU2016219835A1 (en) 2017-09-14
US10351625B2 (en) 2019-07-16
US12312404B2 (en) 2025-05-27
KR20170137067A (ko) 2017-12-12
CY1123259T1 (el) 2021-12-31
US11795220B2 (en) 2023-10-24
CN107580500B (zh) 2023-05-30
SI3258951T1 (sl) 2020-07-31
US20240101669A1 (en) 2024-03-28
US20200148769A1 (en) 2020-05-14
AU2016219835B2 (en) 2020-12-03
DK3653221T3 (da) 2022-10-24
US20160244521A1 (en) 2016-08-25
ES2806800T3 (es) 2021-02-18
HUE049032T2 (hu) 2020-08-28
HRP20201066T1 (hr) 2021-02-05
MX374853B (es) 2025-03-06
LT3258951T (lt) 2020-05-11
US11623955B2 (en) 2023-04-11
US9714289B2 (en) 2017-07-25
MX2017010667A (es) 2018-08-15
PL3258951T3 (pl) 2020-07-27
HUE061084T2 (hu) 2023-05-28
CA2976926A1 (en) 2016-08-25
PT3653221T (pt) 2022-11-08
RU2020128686A (ru) 2020-10-13
SG11201706583PA (en) 2017-09-28
AU2024202336A1 (en) 2024-05-16
LT3295951T (lt) 2020-09-25
DK3653221T5 (da) 2024-08-26
IL254039A0 (en) 2017-10-31
MX2020009461A (es) 2021-02-17
PL3653221T3 (pl) 2022-12-19
PL3295951T3 (pl) 2020-10-05
HUE049791T2 (hu) 2020-10-28
EP3258951B1 (en) 2020-01-29
WO2016134333A9 (en) 2017-02-02
RU2017132214A3 (pt) 2019-08-28
EP3653221B1 (en) 2022-08-03
HK1247569A1 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
IL259495A (en) Antibodies and methods for using them
IL257636A (en) Anti-tigit antibodies and methods of use
ZA201706323B (en) Anti-pvrig antibodies and methods of use
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
SG11201803567XA (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL251868A0 (en) Anti-tim3 antibodies and methods of use
IL251970A0 (en) Anti-cd79b antibodies and methods of use
IL259681A (en) New antibodies against claudin and methods of using them
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
IL246736A0 (en) Anti-jagged1 antibodies and methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use